Abstract 2216P
Background
Diffuse sclerosing variant of papillary thyroid carcinoma (DSVPTC) is commonly observed in young patients, with a median age at diagnosis in the third decade of life. Further, the risk of recurrence is higher with DSVPTC than with classical papillary thyroid carcinoma (PTC). Therefore, this study aimed to describe the clinicopathological and genetic characteristics of patients of different ages with DSVPTC.
Methods
We retrospectively reviewed 397 patients who underwent thyroidectomy for DSVPTC at the Gangnam Severance Hospital, Yonsei University from January 2005 to December 2017. We selected 41 patients through random sampling by their age group, and examined mutations in 119 genes using next-generation sequencing.
Results
The mean age at diagnosis was 36.7±11.6 years, with the majority of patients (163, 41.1%) in their third decades. DSVPTC was predominant in women (276, 69.5%), compared with men. We observed recurrence in 46 patients (11.6%), with regional nodal recurrence being the most common recurrence site (32 patients, 69.6%). The tumour size increased in younger patients (<20 years: 2.69±1.56, 21–30 years: 1.88±1.30, and 31–40 years: 1.55±0.95), those displaying a plateau in their fourth (1.38±0.85) and fifth (1.29±0.91) decades, and those above 61 years of age (1.63±1.45). The initial presentation of cancer was more aggressive in paediatric patients with a larger size, more common multiplicity, and lateral neck metastasis. V-raf murine sarcoma viral oncogene homolog B1 (BRAF), Kirsten rat sarcoma virus (KRAS), and telomerase reverse transcriptase (TERT) displayed relatively higher mutations, compared with other genes.
Conclusions
DSVPTC displayed different clinical, pathological, and molecular profiles, compared with papillary thyroid carcinoma. BRAF, KRAS, and TERT were the most important genetic mutations, with differences depending on the age.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1929P - phase II results from the RINGSIDE phase II/III trial of AL102 for treatment of desmoid tumors
Presenter: Bernd Kasper
Session: Poster session 15
1930P - phase II trial of avelumab in combination with gemcitabine in advanced leiomyosarcoma as a second-line treatment (KCSG UN18-06)
Presenter: Young Saing Kim
Session: Poster session 15
1931P - Ultra-rare sarcomas have worse survival compared to non-ultra-rare sarcomas: A national cancer registry study
Presenter: MIng-Jing Lee
Session: Poster session 15
1932P - First in human trial of CEB-01 for retroperitoneal soft tissue sarcoma
Presenter: Jose Antonio González
Session: Poster session 15
1933P - Perioperative chemotherapy could reduce the risk of recurrence in resected leiomyosarcoma of the vena cava (LMS-VC): A retrospective bi-centric series on 41 patients
Presenter: Thibaud Bertrand
Session: Poster session 15
1934P - Pharmacokinetics of unesbulin in a phase Ib study of patients with advanced leiomyosarcoma
Presenter: Brian Van Tine
Session: Poster session 15
1935P - Exploration of tertiary lymphatic structure in soft tissue sarcoma for the prognostic and immunotherapy response
Presenter: Wang Xiang-Xu
Session: Poster session 15
1936P - Targeted therapy of desmoplastic small round cell tumor guided by multilayered molecular profiling
Presenter: Marcus Renner
Session: Poster session 15
1937P - KM-subtraction meta-analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft-tissue sarcoma
Presenter: Qin Jian Low
Session: Poster session 15
1938P - Assessment of clinical benefit of cancer drugs recommended in National Comprehensive Cancer Network (NCCN) guidelines for advanced soft tissue sarcomas (STS) and bone sarcomas (BS)
Presenter: Maria Aguado Sorolla
Session: Poster session 15